Galectin Therapeutics (GALT) Cash from Financing Activities (2010 - 2026)

Galectin Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $257000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $257000.0 in Q1 2026; TTM through Mar 2026 was $26.7 million, a 25.93% increase from a year earlier, with the FY2025 full-year figure at $26.5 million, down 15.22% from the prior year.
• Cash from Financing Activities declined to $257000.0 in Q1 2026 per GALT's latest filing, from $12.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $12.9 million in Q2 2025 and bottomed at $257000.0 in Q1 2026.
• The 5-year median for Cash from Financing Activities is $10.0 million (2022), against an average of $8.3 million.
• Across the five-year window, Cash from Financing Activities sank 91.49% in 2024 and jumped 1337.96% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $10.0 million in 2022, then changed by 0.0% to $10.0 million in 2023, then sank by 91.49% to $851000.0 in 2024, then soared by 1337.96% to $12.2 million in 2025, then tumbled by 97.9% to $257000.0 in 2026.
• Per Business Quant, the three latest GALT Cash from Financing Activities figures stand at $257000.0 (Q1 2026), $12.2 million (Q4 2025), and $1.3 million (Q3 2025).